Experimental cancer treatments for advanced stages are more effective than previously thought. Some oncology practitioners believe that experimental drugs are harmful - they give false hope to patients because of its low efficiency (long anticipated effectiveness of the experimental treatment with special drugs produced in Canadian pharmacy only at the level of 4-6% of cases). Patients in the final stage of the disease should have greater access to information about the experimental treatment programs, and, accordingly, they and their families should have the right to know what their real chances, with a particular treatment strategy. Scientists believe that the involvement of cancer patients even in the early stages of clinical trials can be very useful for them. Besides, the search for a way out of the situation means continuing the fight against the disease. It is characterized by academic phrase "treatment of metastatic cancer still remains palliative, with a very low probability of complete remission and cure the disease."

Scientific and Ethics Advisory Board


Prof. Dr. med. Michael Weichenthal

Born in 1962 in Husum, Germany, Dr. Weichenthal attended MedicalSchool at Hamburg and Lübeck from 1983 to 1989. After his final exam in Medicine he graduated as Doctor of Medicine (‘magna cum laude’) during medical training as  resident at the Department of Dermatology at the University of  Hamburg. In 1994 he became board certified as Dermatologist and moved to the DermatologicalCenter in Buxtehude, Germany. In 1996 he received board certification as Allergologist. From 1996 to 2001 he served as senior consultant at the Department of  Dermatology at St.George’s Hospital in Hamburg, Germany.

Following a scholarship as a research fellow at the Department of Dermatology, University of Münster in 2000, he moved to Kiel in 2001 for a research postion in dermato-epidemiology at the Department of Dermatology at the University of Kiel, Germany. In 2004 he became assistant professor, and since 2009 a full professor of dermatology at the Kiel university.

His main interests are in epidemiology and genetics, in particular in psoriasis and skin cancer including primary cutaneous lymphomas. He works and publishes on general systems for epidemiologic methodology and classification of skin diseases. He is member of several scientific societies and editorial boards, member of the board of the German Dermato-Oncology Group (DeCOG) and co-chair of the Topic Advisory Group for the ICD-11 dermatology classification at the World Health Organization.

Axel Zurhausen3

Prof. Dr. Axel zur Hausen

Professor Axel zur Hausen studied medicine at the University of Freiburg, Germany, and graduated in 1994. He received his M.D. degree in 1996 at the Institute of Biochemistry, University of Freiburg. He was trained in Surgical Pathology at the Departments of Pathology in Zürich, Düsseldorf and Amsterdam, and received his board certification  in 2002. From 2002 to 2004 he worked as pathologist at the Institute of Pathology of the University Hospital in Cologne, Germany. In 2004 he received his Ph.D. at the Free University Amsterdam based on his thesis “Epstein-Barr virus-carrying gastric carcinomas: pathogenesis and clinical aspects“. In July 2004 he was appointed Full University Professor (C3) at the University Medical Center Freiburg, Germany and in 2005 he was appointed Deputy Director of the Institute of Pathology of the University Medical Center Freiburg. In 2010, he was appointed University Professor of Pathology and Chairman of the Department of Pathology at Maastricht University Medical Center.


Prof. Dr. Eckhart Kaempgen

Dr. Kaempgen has been working in the field of Dendritic Cells since more than 20 years and continuously contributed to both, basic research on the immunobiology of DCs and translational research resulting in DC based treatment of tumor patients (>100 peer reviewed publications). He received his MD in 1987 at the medical school of the LMU Munich and, before starting his dermatology fellowship at the Univ. of Würzburg (Günter Burg, Eva Bröcker) in 1990, was trained as research associate at the Depts. of Immunology, Munich (Gert Riethmüller) and Dermatology, Univ. of Innsbruck (Gerold Schuler, Peter Fritsch). From the very first beginning Dr. Kaempgen was involved in the development of today´s standard method to generate human DCs from peripheral blood monocytes and especially strategies to load DC with tumor antigens by RNA transfection, which was developed in close cooperation with Eli Gilboa at the Duke University, Durham. Following a position as Director of Immunology, Merix* Inc., Durham, NC Dr. Kaempgen in 2003 became Associate Professor for Strategies of Cellular Immunotherapy at the Dep. Dermatology, Univ. of Erlangen (head: Gerold Schuler) and responsible senior dermatologist for skin tumor patients. Since 2008 he has been heading the interdisciplinary skin (melanoma) tumor board of the Erlangen University Hospital and PI of > 20 clinical trials in melanoma including targeted therapy with Sorafenib, Vemurafenib, Dabrafenib, Trametinib, Nivolumab and Ipilimumab.

In September 2013 Prof. Kaempgen left the Unversity of Erlangen to found the Dermatologikum Berlin together with Uwe Trefzer, Rainer Rupprecht, Kristian Reich and Volker Steinkraus.